Randomized controlled trial· 2014

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation

Stanley TL|et al.

JAMA

PubMed: 25038357
Evidence level: high
Verification: verified

Summary

Randomized study evaluating visceral and liver fat during six months of tesamorelin.

Limitations

Relatively small and limited to people with HIV and abdominal fat accumulation.

Linked peptides

Tesamorelin

Important PeptiBrief is an educational information platform. It does not diagnose, prescribe, sell peptides, recommend dosing, encourage self-experimentation or replace qualified medical care. Published scientific evidence is kept separate from community observations and uncertainty.